These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15694910)

  • 1. Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
    Eriksson P
    Am J Med; 2005 Feb; 118(2):199-200; author reply 200. PubMed ID: 15694910
    [No Abstract]   [Full Text] [Related]  

  • 2. When increased therapeutic benefit comes at increased cost.
    Wood AJ
    N Engl J Med; 2002 Jun; 346(23):1819-21. PubMed ID: 12050345
    [No Abstract]   [Full Text] [Related]  

  • 3. CAPRIE trial.
    Davie AP; Love MP
    Lancet; 1997 Feb; 349(9048):355; author reply 356. PubMed ID: 9024396
    [No Abstract]   [Full Text] [Related]  

  • 4. Clopidogrel plus aspirin in atrial fibrillation.
    Lee YE; DeZee KJ
    N Engl J Med; 2009 Sep; 361(13):1313-4; author reply 1314-5. PubMed ID: 19780215
    [No Abstract]   [Full Text] [Related]  

  • 5. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Ramsey SD
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572583
    [No Abstract]   [Full Text] [Related]  

  • 6. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 7. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAPRIE trial.
    Barer D
    Lancet; 1997 Feb; 349(9048):355-6. PubMed ID: 9024397
    [No Abstract]   [Full Text] [Related]  

  • 10. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Armstrong EC
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572582
    [No Abstract]   [Full Text] [Related]  

  • 11. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Akinlade BK
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12571267
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
    Heeg B; van Gestel A; Hout Bv; Olsen J; Haghfelt TH
    Ugeskr Laeger; 2006 Aug; 168(35):2911-5. PubMed ID: 16982022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Haldemann R; Lüscher TF; Szucs TD
    Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of aspirin in MATCH.
    Eriksson P
    Lancet; 2004 Nov 6-12; 364(9446):1661; author reply 1662-3. PubMed ID: 15530615
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
    Rothlisberger JM; Ovbiagele B
    J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin and Plavix: what every clinical nurse specialist should know now.
    O'Malley P
    Clin Nurse Spec; 2007; 21(1):13-5. PubMed ID: 17213734
    [No Abstract]   [Full Text] [Related]  

  • 19. Antifibrinolytics may be cost saving among recent recipients of combined acetylsalicylic acid and clopidogrel who undergo coronary artery bypass graft surgery.
    Ray JG; Hamielec CM
    Can J Cardiol; 2004 Jun; 20(8):829-30. PubMed ID: 15229768
    [No Abstract]   [Full Text] [Related]  

  • 20. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
    Karnon J; Brennan A; Pandor A; Fowkes G; Lee A; Gray D; Coshall C; Nicholls C; Akehurst R
    Curr Med Res Opin; 2005 Jan; 21(1):101-12. PubMed ID: 15881481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.